Skip to content

Efficacy evaluation of the Melissa officinalis syrup in treatment of children's anxiety symptoms with Attention Deficit Hyperactivity Disorder

Efficacy evaluation of the Melissa officinalis syrup in treatment of children's anxiety symptoms with Attention Deficit Hyperactivity Disorder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221001056065N1
Enrollment
30
Registered
2022-11-07
Start date
2022-11-01
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Attention-deficit hyperactivity disorder, predominantly inattentive type

Interventions

Intervention 1: Intervention group: Melissa officinalis syrup of Ehyateb Daru Tabiat company with a dose of 0.2 cc per kilogram of weight in two divided doses recipients. Intervention 2: Control group

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 12 Years

Inclusion criteria

Inclusion criteria: The patient with DSM V ADHD criteria, Absence of other systemic or psychiatric disorders, IQ in the normal range at least three months have passed since their standard drug treatment, Completion of the informed consent form by the parent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Revised Children's Anxiety Scale. Timepoint: in 3 and 6 weeks. Method of measurement: The amount of change in the revised children's anxiety scale questionnaire.;Attention deficit hyperactivity disorder scoring scale questionnaires. Timepoint: in 3 and 6 weeks. Method of measurement: The amount of change in attention deficit hyperactivity disorder scoring scale.

Secondary

MeasureTime frame
Revised Children's Manifest Anxiety Scale score. Timepoint: week 3 and 6. Method of measurement: The amount of change in the anxiety score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Moharari

Mashhad University of Medical Sciences

MoharariF1@mums.ac.ir+98 51 3700 2202

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026